# Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site) - Incorporation of Mayo Clinic Cancer Center as an Affiliated Center

> **NIH NIH UM1** · DANA-FARBER CANCER INST · 2021 · $100,000

## Abstract

PROJECT SUMMARY/ABSTRACT
This application is being submitted to request additional funds for Mayo Clinic Cancer Center (MCCC) as an
Affiliated Organization (AO) to the Dana-Farber/Harvard Cancer Center (DF/HCC) Experimental Therapeutics
Clinical Trials Network (ETCTN) Lead Academic Organization (LAO). MCCC investigators, led by Dr. Alex A.
Adjei and representing the Mayo Clinic Rochester, Florida and Arizona sites, have been incorporated into the
DF/HCC LAO Leadership and Steering Committee, Governance Committee and Translational Core.
Additionally, they are participating as disease-focused clinical investigators, with support from MCCC
interventional radiology, pathology and biostatistics. Work conducted under this supplement will facilitate the
continuation and completion of MCCC-led ETCTN trials that address inhibitors of DNA repair and tumor
metabolism, as well as immuno-oncology combinations and antibody drug conjugates across solid tumors and
hematologic malignancies. Emphasis will be placed on the continued mentorship of MCCC early career
investigators, manifested in part by support afforded by the DF/HCC LAO Scholars in Cancer Experimental
Therapeutics (SCET) Program. As an AO, it is anticipated that over the next year, MCCC investigators will
enroll a minimum of 20 patients to ETCTN trials and submit Project Team Member Applications (PTMAs) and
other clinical trial proposals culminating in at least two approved letters of intent (LOIs). MCCC investigators
will also coordinate with DF/HCC to ensure that the LAO consistently demonstrates at least 30% network
participation, with at least 6 trials open in relevant disease-focused disciplines with 10 enrollments per disease
group. Finally, MCCC investigators will also work with DF/HCC to increase the enrollment of under-
represented and rural populations to ETCTN trials by leveraging the catchment area encompassed by MCCC
sites.

## Key facts

- **NIH application ID:** 10393266
- **Project number:** 3UM1CA186709-06S1
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** KEITH T FLAHERTY
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $100,000
- **Award type:** 3
- **Project period:** 2014-03-13 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10393266

## Citation

> US National Institutes of Health, RePORTER application 10393266, Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site) - Incorporation of Mayo Clinic Cancer Center as an Affiliated Center (3UM1CA186709-06S1). Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/grant/nih/10393266. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*